SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Condition: Type 2 Diabetes Interventions: Drug: Dapagliflozin; Drug: Metformin Sponsors: The George Institute; The University of New South Wales; Monash University; University of Sydney Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Forxiga | Metformin | Research | SGLT2 Inhibitors | Wales Health